Related Experiment Video

Updated: Mar 25, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

9.0K

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated

Vinit Kumar1, Pingyan Cheng2, Thomas Condamine1

  • 1The Wistar Institute, Philadelphia, PA 19104, USA.

Immunity
|February 18, 2016
PubMed

Insights

Tumor progression is driven by myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Hypoxia in tumors downregulates STAT3 activity via CD45, controlling MDSC to TAM differentiation and offering a therapeutic target.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Signaling

Background:

  • Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are crucial for tumor progression and metastasis.
  • Understanding the regulatory mechanisms controlling TAM differentiation from monocytic precursors is vital for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of Signal Transducer and Activator of Transcription 3 (STAT3) in regulating the differentiation of MDSCs into TAMs within the tumor microenvironment.
  • To elucidate the molecular mechanisms, including the involvement of hypoxia and CD45, that lead to STAT3 downregulation and subsequent TAM differentiation.

Main Methods:

  • Analysis of STAT3 activity in myeloid cells within the tumor microenvironment.
  • Investigating the impact of hypoxia on myeloid cells and STAT3 signaling.
  • Assessing the role of CD45 tyrosine phosphatase activity and its regulation by sialic acid in controlling STAT3 function.

Main Results:

  • STAT3 activity downregulation was identified as a key factor controlling TAM differentiation from monocytic precursors in the tumor site.
  • Hypoxia was found to decrease STAT3 activity in myeloid cells, but not in tumor cells.
  • Upregulation of CD45 tyrosine phosphatase activity in MDSCs, mediated by sialic acid-regulated disruption of CD45 dimerization, was responsible for STAT3 downregulation.

Conclusions:

  • STAT3 plays a unique and critical role in the tumor environment by controlling the differentiation of MDSCs into TAMs.
  • The STAT3 regulatory pathway, influenced by hypoxia and CD45 activity, represents a potential therapeutic target for inhibiting tumor progression and metastasis.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

905

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K